Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Completed × NETWORK × Breast Cancer Invasive Nos × Clear all

Phase

Status

Sponsor Class

OTHER 1 NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 163 Leukemia 138 Lymphoma 101 Lung Neoplasms 99 Carcinoma, Non-Small-Cell Lung 92 Precursor Cell Lymphoblastic Leukemia-Lymphoma 80 Sarcoma 77 Prostatic Neoplasms 77 Central Nervous System Neoplasms 73 Ovarian Neoplasms 67 Colorectal Neoplasms 66 Head and Neck Neoplasms 63 Rectal Neoplasms 53 Squamous Cell Carcinoma of Head and Neck 51 Multiple Myeloma 49 Leukemia, Myeloid, Acute 48 Colonic Neoplasms 48 Neuroblastoma 44 Brain Neoplasms 42 Uterine Cervical Neoplasms 41 Lymphoma, Large B-Cell, Diffuse 39 Carcinoma, Ovarian Epithelial 38 Glioblastoma 37 Neoplasm Metastasis 36 Fallopian Tube Neoplasms 35 Astrocytoma 35 Leukemia, Lymphocytic, Chronic, B-Cell 34 Burkitt Lymphoma 34 Melanoma 32 Hodgkin Disease 31

Interventions

acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 1 Triptorelin Pamoate 1 Letrozole 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02005887 2019-05-29

TREND

ETOP IBCSG Partners Foundation

Phase 2 Completed

51 enrolled 10 charts

Breast Cancer Invasive Nos

Data powered by HemOnc (CC BY 4.0) Colophon ⚡